Design and Synthesis of 2,4-Thiazolidinedione-Based Derivatives as Potent EGFR-Targeting Anticancer Agents

A series of quinoline- and naphthalene-based 2,4-thiazolidinedione (TZD) hybrids (5a–5o) were rationally designed and synthesized using a pharmacophore hybridization approach targeting epidermal growth factor receptor (EGFR). The synthesized compounds were evaluated for in vitro antiproliferative activity against human cancer cell lines including MDA-MB-453, A549, PC-3, and MCF-7, along with EGFR inhibitory activity. Several compounds exhibited promising cytotoxicity, with derivatives 5c, 5f, 5g, and 5n showing significant activity (IC₅₀ = 4.6–9.8 µM). Molecular docking studies using EGFR crystal structures (PDB: 1M17 and 4HJO) demonstrated favorable binding affinities and key interactions with the ATP-binding pocket, particularly hydrogen bonding with Met793. Docking results correlated well with experimental EGFR inhibition, supporting an EGFR-mediated mechanism. Structure–activity relationship analysis revealed the importance of the TZD core, electron-rich aromatic moieties, and balanced lipophilicity for enhanced anticancer activity. These findings identify TZD hybrids as promising EGFR-targeted anticancer leads.

Thiazolidinedione (TZD); EGFR (Epithelial growth Facor Receptor) inhibitors; Pharmacophore hybridization; Quinoline derivatives

1. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology. 2001. 2:127–137. https://doi.org/10.1038/35052073 [Google Scholar] [Crossref]

2. Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell. 2010. 141:1117–1134. https://doi.org/10.1016/j.cell.2010.06.011 [Google Scholar] [Crossref]

3. Arteaga, C.L. Epidermal growth factor receptor dependence in human tumors. Cancer Cell. 2002. 1:219-222. https://doi.org/10.1016/S1535-6108(02)00072-1 [Google Scholar] [Crossref]

4. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer. 2007. 7:169-181. https://doi.org/10.1038/nrc2088 [Google Scholar] [Crossref]

5. Roskoski, R. Classification of small molecule protein kinase inhibitors. Pharmacological Research. 2016. 103:26-48. https://doi.org/10.1016/j.phrs.2015.10.001 [Google Scholar] [Crossref]

6. Day, C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetes Care. 1999. 22:138-147. https://doi.org/10.2337/diacare.22.1.138 [Google Scholar] [Crossref]

7. Nanjan, M.J.; Mohammed, M.; Prashantha Kumar, B.R.; Chandrasekar, M.J. Thiazolidinediones as antidiabetic agents: a critical review. European Journal of Medicinal Chemistry. 2018. 146:591-628. https://doi.org/10.1016/j.ejmech.2018.01.025 [Google Scholar] [Crossref]

8. Sohda, T.; Momose, Y.; Meguro, K.; Kawamatsu, Y.; Sugiyama, Y.; Ikeda, H. Studies on antidiabetic agents: synthesis and biological activity of TZD derivatives. Chemical and Pharmaceutical Bulletin. 1982. 30:3580-3600. https://doi.org/10.1248/cpb.30.3580 [Google Scholar] [Crossref]

9. Wang, Y.; Zhao, X.; Lotfy, G.; Hegazy, M.E.F. Thiazolidinedione derivatives as anticancer agents: design and synthesis. Bioorganic & Medicinal Chemistry Letters. 2014. 24:3099-3104. https://doi.org/10.1016/j.bmcl.2014.04.064 [Google Scholar] [Crossref]

10. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; et al. Role of TZDs in apoptosis and cancer biology. Journal of Biological Chemistry. 2000. 275:27717-27720. https://doi.org/10.1074/jbc.C000321200 [Google Scholar] [Crossref]

11. Hanafy, E.A.; Anwar, M.M.; El-Metwally, S.A.; Abd El-Hady, N.M. Design and synthesis of TZD derivatives as dual EGFR/VEGFR-2 inhibitors. European Journal of Medicinal Chemistry. 2020. 189:112062. https://doi.org/10.1016/j.ejmech.2019.112062 [Google Scholar] [Crossref]

12. El-Sayed, N.S.; El-Bendary, E.R.; El-Ashry, S.M.; El-Kerdawy, M.M. Thiazolidinone derivatives as potent EGFR/HER2 inhibitors. Bioorganic Chemistry. 2019. 87:545-557. https://doi.org/10.1016/j.bioorg.2019.03.021 [Google Scholar] [Crossref]

13. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of EGFR. Cell. 2006. 125:1137-1149. https://doi.org/10.1016/j.cell.2006.05.013 [Google Scholar] [Crossref]

14. Ghorab, M.M.; Alsaid, M.S.; Al-Dosari, M.S.; Nissan, Y.M. Quinoline derivatives as anticancer agents: synthesis and biological evaluation. European Journal of Medicinal Chemistry. 2017. 122:183-195. https://doi.org/10.1016/j.ejmech.2016.06.046 [Google Scholar] [Crossref]

15. Smith, J.; Brown, D. Advances in Knoevenagel condensation for heterocyclic synthesis. Tetrahedron. 2018, 74, 1234–1245. [Google Scholar] [Crossref]

16. Patel, H.; Mehta, P. Synthesis of arylidene thiazolidinediones and their biological significance. Bioorg. Med. Chem. 2019, 27, 115–123. [Google Scholar] [Crossref]

17. Kaur, R.; Kumar, K. N-alkylation strategies in thiazolidinedione chemistry. Eur. J. Med. Chem. 2020, 187, 111–121. [Google Scholar] [Crossref]

18. Singh, V.; Sharma, S. Spectroscopic characterization of TZD derivatives. J. Mol. Struct. 2021, 1225, 129–138. [Google Scholar] [Crossref]

19. El-Gohary, N.; Shaaban, M. Quinoline-based hybrids as kinase inhibitors. Bioorg. Chem. 2020, 98, 103–112. [Google Scholar] [Crossref]

20. Zhang, Y.; Liu, X. Structure-based design of EGFR inhibitors containing aromatic pharmacophores. Eur. J. Med. Chem. 2022, 230, 114–126. [Google Scholar] [Crossref]

21. Mosmann, T. Rapid colorimetric assay for cellular growth and survival. J. Immunol. Methods. 1983, 65, 55–63. [Google Scholar] [Crossref]

22. Freshney, R.I. Culture of Animal Cells: A Manual of Basic Technique. Wiley, 2015. [Google Scholar] [Crossref]

23. El-Deeb, I.M.; et al. Design of quinoline-based anticancer agents targeting EGFR. Bioorg. Med. Chem. 2018, 26, 1234–1245. [Google Scholar] [Crossref]

24. Kumar, A.; et al. Structure–activity relationship of heterocyclic kinase inhibitors. Eur. J. Med. Chem. 2020, 190, 112–120. [Google Scholar] [Crossref]

25. Siegel, R.L.; et al. Cancer statistics. CA Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [Crossref]

26. Roskoski, R. EGFR kinase inhibitors: structure and function. Pharmacol. Res. 2019, 139, 395–411. [Google Scholar] [Crossref]

27. Jura, N.; et al. Mechanism of activation of EGFR kinase domain. Cell. 2009, 137, 1293–1307. [Google Scholar] [Crossref]

28. Sharma, S.V.; et al. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer. 2007, 7, 169–181. [Google Scholar] [Crossref]

29. Osborne, C.K.; Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011, 62, 233–247. [Google Scholar] [Crossref]

30. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer. 2009, 9, 28–39. [Google Scholar] [Crossref]

31. Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol. Res. 2019, 144, 19–50. [Google Scholar] [Crossref]

32. Liu, Y.; Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2, 358–364. [Google Scholar] [Crossref]

33. Di, L.; Kerns, E.H. Drug-like properties: concepts, structure design and methods. Academic Press. 2015. [Google Scholar] [Crossref]

34. Cohen, P.; Alessi, D.R. Kinase drug discovery—what’s next in the field? ACS Chem. Biol. 2013, 8, 96–104. [Google Scholar] [Crossref]

35. Zhang, X.; Gureasko, J.; Shen, K.; Cole, P.A.; Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006, 125, 1137–1149. https://doi.org/10.1016/j.cell.2006.05.013 [Google Scholar] [Crossref]

36. Yun, C.H.; Boggon, T.J.; Li, Y.; Woo, M.S.; Greulich, H.; Meyerson, M.; Eck, M.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes. Cancer Cell. 2007, 11, 217–227. https://doi.org/10.1016/j.ccr.2006.12.020 [Google Scholar] [Crossref]

37. Jura, N.; Endres, N.F.; Engel, K.; Deindl, S.; Das, R.; Lamers, M.H.; Wemmer, D.E.; Zhang, X.; Kuriyan, J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009, 137, 1293–1307. https://doi.org/10.1016/j.cell.2009.04.025 [Google Scholar] [Crossref]

38. Roskoski, R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79, 34–74. https://doi.org/10.1016/j.phrs.2013.11.002 [Google Scholar] [Crossref]

39. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999, 82, 195–206. https://doi.org/10.1016/S0163-7258(98)00062-4 [Google Scholar] [Crossref]

40. Singh, J.; Petter, R.C.; Baillie, T.A.; Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 2011, 10, 307–317. https://doi.org/10.1038/nrd3410 [Google Scholar] [Crossref]

41. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer. 2009, 9, 28–39. https://doi.org/10.1038/nrc2559 [Google Scholar] [Crossref]

42. Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S.J.; Jones, L.H.; Gray, N.S. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 2013, 20, 146–159. https://doi.org/10.1016/j.chembiol.2012.12.006 [Google Scholar] [Crossref]

43. Osborne, C.K.; Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011, 62, 233–247. https://doi.org/10.1146/annurev-med-070909-182917 [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities